1402 Final PSD

MSAC noted that the evidence base presented for the use of MTA in liver cancer was generally of lower quality. Systematic reviews comparing MTA with radiofrequency ablation (RFA), the comparator, were available but the majority of studies included in these reviews were retrospective cohort studies with historical control groups, which are considered to be lower level evidence. ................
................